Search - tctmd.com

Displaying 381 - 400 of 2485

Sort: Relevancy | Date

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

November 27, 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

News Conference News AHA 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

November 17, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

‘Proof-of-Concept’ AI-ECG May Improve STEMI Care: ARISE

News Conference News AHA 2023

‘Proof-of-Concept’ AI-ECG May Improve STEMI Care: ARISE

Yael L. Maxwell

November 17, 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

News Conference News AHA 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

November 16, 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

November 15, 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

November 14, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

News Conference News AHA 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

November 12, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

News Daily News

SAVR 5-Year Survival Tops 92% in Low-Risk Patients: STS Registry

Yael L. Maxwell

October 20, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.